Navigation Links
Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial,Data

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 19, 2007 - Javelin Pharmaceuticals (AMEX: JAV) announced today that its product candidate Rylomine(TM) (intranasal morphine) successfully met its primary clinical endpoint, the Sum of the Pain Intensity Difference (SPID) scores over 0-24 hours postoperatively. In this first of two pivotal Phase 3 studies, patients with moderate-to-severe pain after elective orthopedic surgery were given 7.5 mg Rylomine every hour as needed, 15 mg Rylomine every 3 hours as needed, or 7.5 mg intravenous (IV) morphine every 3 hours as needed. Patients in each of the three active treatment groups had significantly better (p less than .01 or less) SPID scores over 24 hours than the corresponding placebo groups.

"Parenteral morphine is the gold standard for postoperative analgesia," commented Dr. Daniel B. Carr, CEO and CMO of Javelin Pharmaceuticals. "Today's gratifying results extend our prior positive study findings showing that Rylomine is a simple, effective alternative to more complex, cumbersome and costly methods of postoperative opioid analgesia. We look forward to continuing the development of this innovative product candidate."

There were no serious adverse events related to the study drug. Local adverse events associated with nasal administration (bad taste, throat irritation, instillation site reaction, nasal erythema, nasal irritation) were more common with Rylomine or intranasal placebo than the intravenous morphine groups. General systemic adverse events related to active drug were similar across morphine treatment groups regardless of route of administration and consistent with morphine's known pharmacologic effects (dizziness, nausea, transient decreased oxygen saturation, and vomiting).

Full analyses of the data are ongoing and will be reported when available.

About the Study

This study, termed MOR-003, involved 278 randomized patients with moderate
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine) Data Published in Pain Medicine
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:8/20/2014)... , Aug. 20, 2014  Quantum Materials Corporation ... sets of patent families from Bayer Technology Services GmbH, ... for Bayer AG of Leverkusen, Germany ... provide broad intellectual property protection for advances ... quantum dot (QD) manufacturing. In addition, the Bayer ...
(Date:8/20/2014)... Glenmark Pharmaceuticals S.A. (GPSA), ... India (GPL), announces the discovery and initiation of ... candidate, GBR 1302, a HER2xCD3 bispecific antibody. GBR ... Biologics Research Centre located in La Chaux-de-Fonds, ... on Glenmark,s innovative BEAT antibody technology platform which ...
(Date:8/20/2014)... 20, 2014 Phase I Trial ... US  KalVista Pharmaceuticals ("KalVista"), an ophthalmology company ... announces that it has begun a Phase I, First ... KVD001, for the treatment of DME. The study,s Principal ... Eye Institute, Joslin Diabetes Center; Harvard Medical School Department ...
Breaking Medicine Technology:Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 2Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 3Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 4Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4
... Information Systems ("SIS"), a leader in perioperative ... leadership in achieving clinical, financial, and operational goals ... the company,s annual client conference, the 2012 SIS ... systems exemplifying the innovative use of information technology ...
... 2012 Top leaders representing America,s advanced medical ... public policy issues affecting job creation and medical innovation and ... billion medical device tax set to begin in January 2013. ... Renacci (R-Ohio) joined Walter M Rosebrough, president and CEO of ...
Cached Medicine Technology:Surgical Information Systems Recognizes Clients for Financial, Clinical, and Operational Improvements 2Surgical Information Systems Recognizes Clients for Financial, Clinical, and Operational Improvements 3Surgical Information Systems Recognizes Clients for Financial, Clinical, and Operational Improvements 4AdvaMed & BioOhio Discuss MedTech Impact on Ohio's Economy, Job Creation 2AdvaMed & BioOhio Discuss MedTech Impact on Ohio's Economy, Job Creation 3
(Date:8/20/2014)... CA (PRWEB) August 20, 2014 If old ... found a cure for it. With extensive research on HGH ... named ‘MetroMD’ claims to have perfected the art of rubbing ... a brand new younger look with their revolutionary anti-aging hormone ... of the 21st century fountain of youth, the MD of ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 The ... a five-year, $1.24 million Science Education Partnership Award ... to support NAHN’s collaborative project with the Hispanic ... Health Careers. , This collaborative NIH R25 program ... cultural and linguistic diversity among health professionals by ...
(Date:8/20/2014)... Utah (PRWEB) August 20, 2014 Today, ... new information on open enrollment for 2015. , According ... insurance coming up in November, employees are encouraged to ... seeking coverage in 2015, the open enrollment period will ... During open enrollment 2015 individuals can purchase a new ...
(Date:8/20/2014)... 2014 Attendees of Seedstock’s 3rd Annual ... at Los Angeles’ first multi-faceted food production business incubator ... blossoming 1.5-acre high school campus urban farming operation in ... in the L.A. Art District. , The field trip, ... agriculture, will kick off Seedstock’s “Reintegrating Ag: Local Food ...
(Date:8/20/2014)... MA (PRWEB) August 20, 2014 Verndale ... annual Inc. 500|5000 list; an exclusive list ranking the ... list are ranked according to their yearly percentage revenue ... the 8th time on the Inc. 5000 list where ... Technology Company, Verndale offers its clients a wide range ...
Breaking Medicine News(10 mins):Health News:MetroMD Offers Revolutionary Anti-aging Hormone Therapy in Hollywood Area 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 3Health News:Seedstock Sustainable Agriculture Conference’s Urban Farm Field Trip to Offer First Look at Los Angeles’ Premier Food Business Incubator 2Health News:Seedstock Sustainable Agriculture Conference’s Urban Farm Field Trip to Offer First Look at Los Angeles’ Premier Food Business Incubator 3Health News:For the 8th Time, Verndale Has Been Honored on the Inc. 5000 List 2
... Inc. (Nasdaq: CADX ) announced today that it ... a private placement approximately 12 million shares of the Company,s ... million additional shares of the Company,s common stock, for aggregate ... paid for the common stock, $7.13 per share, is equal ...
... 4:00 PM ET - VALENCIA, Calif., Feb. 17 /PRNewswire-FirstCall/ ... ) today reported financial results for the fourth quarter ... of 2008, total operating expenses were $81.8 million, compared ... Research and development (R&D) expenses increased by $2.0 million ...
... bulk of cases, study finds, , , TUESDAY, Feb. 17 (HealthDay ... loss also have eye disorders, a new study has found. ... ear or to the nerves that link the ear to ... according to background information in the study. Half of all ...
... announced today that it has,received certification of its full ... Standards by the Jefferson School of,Population Health. , ... 10 Quality and Safety Standards in,March of 2007 with ... as its Clinical Advisory Board. A condition of CCA,membership ...
... HotHead Technologies, Inc. today,announced that the technology they ... Kennesaw State University researchers as an early,warning ... "It,s exciting news that research from a university as ... verify much earlier than we anticipated, in,the preliminary stages ...
... Light Press, LLC announces the audio edition of "That,s ... written by co-authors Lil Ingram and Marlene Lee, and ... of HOPE is available in MP3 format at no ... will also be available via the website for the ...
Cached Medicine News:Health News:Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock 2Health News:Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock 3Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2008 Financial Results 2Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2008 Financial Results 3Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2008 Financial Results 4Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2008 Financial Results 5Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2008 Financial Results 6Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2008 Financial Results 7Health News:Eye Problems, Hearing Loss May Be Linked 2Health News:RediClinic Meets Strict Quality and Safety Standards for Retail Clinics 2Health News:RediClinic Meets Strict Quality and Safety Standards for Retail Clinics 3Health News:RediClinic Meets Strict Quality and Safety Standards for Retail Clinics 4Health News:HotHead Technologies' Heat Sensor Shows Exciting Potential by Kennesaw State University Researchers 2Health News:'That's My Hope' Audio Edition Released 2Health News:'That's My Hope' Audio Edition Released 3
... reads, writes and prints "Smart" labels. As ... or barcode on the label surface. SATO's ... a range of applications, including: Compliance Labeling, ... Tagging, Retail Labeling, Product Authentication. CL408e RFID ...
... is a core software component ... which enables location-based applications in ... capabilities of the AeroScout Engine ... management of AeroScout hardware and ...
... The Kisses tag is part ... of the Hugs system. The Kisses ... mother after it has been bonded ... her baby. he two tags remain ...
... Radianse active-RFID-tags can be ... For example, that a device ... complete or that a patient ... Every message from an ID-tag ...
Medicine Products: